Promising autoimmune biotech gets $40 million as celiac drug is pushed to clinic

After four years of preclinical work, one of the more promising companies in the hunt for a drug to treat celiac disease is getting bought out by a collaborator, which will now get a new infusion of cash to drive it into its first clinical trials.